Press Releases from Lumateperone- Pharma Proff (1 total)
Lumateperone– Drug Launch Insight, 2018
Lumateperone by Intra-Cellular Therapies Inc., has multiple mechanisms, such as that of a potent serotonin 5-HT2A receptor antagonist; a dopamine receptor phosphoprotein modulator (DPPM), acting…
Go To Page:
